127 related articles for article (PubMed ID: 33604096)
1. Perceptions of Health-Care Workers of the Cost and Safety of Oral Oncolytic Agents for Patients: A Survey.
Tompkinson M; Fine K; Gruber D; Abraham I; McBride A
J Adv Pract Oncol; 2020; 11(4):354-365. PubMed ID: 33604096
[TBL] [Abstract][Full Text] [Related]
2. 2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard.
Mackler E; Segal EM; Muluneh B; Jeffers K; Carmichael J
J Oncol Pract; 2019 Apr; 15(4):e346-e355. PubMed ID: 30860937
[TBL] [Abstract][Full Text] [Related]
3. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions.
Streeter SB; Schwartzberg L; Husain N; Johnsrud M
Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP38-44. PubMed ID: 21711076
[TBL] [Abstract][Full Text] [Related]
4. Barriers to receipt of novel oral oncolytics: A single-institution quality improvement investigation.
Wang AA; Tapia C; Bhanji Y; Campbell C; Larsen D; Gross D; Ganatra S; Qodsi M; Tellez C; Jain S
J Oncol Pharm Pract; 2020 Mar; 26(2):279-285. PubMed ID: 30943846
[TBL] [Abstract][Full Text] [Related]
5. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions.
Streeter SB; Schwartzberg L; Husain N; Johnsrud M
J Oncol Pract; 2011 May; 7(3 Suppl):46s-51s. PubMed ID: 21886519
[TBL] [Abstract][Full Text] [Related]
6. Emerging trends in cancer care: health plans' and pharmacy benefit managers' perspectives on changing care models.
Greenapple R
Am Health Drug Benefits; 2012 Jul; 5(4):242-53. PubMed ID: 24991323
[TBL] [Abstract][Full Text] [Related]
7. The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices.
Salgado TM; Mackler E; Severson JA; Lindsay J; Batra P; Petersen L; Farris KB
Support Care Cancer; 2017 Jun; 25(6):1797-1807. PubMed ID: 28108821
[TBL] [Abstract][Full Text] [Related]
8. Oral oncolytic monitoring pilot with patient-reported outcomes and adherence assessments.
Signorelli J; Bell C; Monaco S
J Oncol Pharm Pract; 2022 Sep; ():10781552221112603. PubMed ID: 36113036
[TBL] [Abstract][Full Text] [Related]
9. Expanding pharmacy practice through the use of pharmacy technicians as process navigators to facilitate patient access of oral anticancer agents.
Lau G; Alwan L; Chi M; Lentz M; Hone K; Segal E
J Am Pharm Assoc (2003); 2019; 59(4):586-592. PubMed ID: 31036528
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
[TBL] [Abstract][Full Text] [Related]
11. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
[TBL] [Abstract][Full Text] [Related]
12. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
13. Patient out-of-pocket payments for oral oncolytics: results from a 2009 US claims data analysis.
Raborn ML; Pelletier EM; Smith DB; Reyes CM
Am J Manag Care; 2012 May; 18(5 Spec No. 2):SP57-64. PubMed ID: 22693982
[TBL] [Abstract][Full Text] [Related]
14. Pharmacist-driven medication reconciliation reduces oral oncolytic medication errors during transitions of care.
Heffner C; Dillaman M; Hill J
Am J Health Syst Pharm; 2020 Nov; 77(Supplement_4):S100-S104. PubMed ID: 32725142
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
16. Impact of oral oncolytic initiation on medication adherence for pre-existing comorbid chronic conditions.
Dashputre AA; S Gatwood K; Schmidt J; Gatwood J
J Oncol Pharm Pract; 2020 Jun; 26(4):835-845. PubMed ID: 31575355
[TBL] [Abstract][Full Text] [Related]
17. Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(27):1-66. PubMed ID: 23074532
[TBL] [Abstract][Full Text] [Related]
18. Pharmacists' knowledge of the safety of antibiotics for systemic use.
Yakimova Y
Int J Risk Saf Med; 2015; 27 Suppl 1():S11-2. PubMed ID: 26639686
[TBL] [Abstract][Full Text] [Related]
19. Pharmacists' roles in oncology pharmacy services: Results of a global survey.
Holle LM; Harris CS; Chan A; Fahrenbruch RJ; Labdi BA; Mohs JE; Norris LB; Perkins J; Vela CM
J Oncol Pharm Pract; 2017 Apr; 23(3):185-194. PubMed ID: 26854267
[TBL] [Abstract][Full Text] [Related]
20. Do treatment patterns alter beliefs cancer patients hold regarding oral oncolytic agents?
Sikorskii A; Given CW; Given BA; Vachon E; Marshall V; Krauss JC; Banik A; Majumder A
Psychooncology; 2018 Mar; 27(3):1005-1012. PubMed ID: 29232502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
